MedTrace Logo

Benefits of Trimetazidine in MASLD Patients

NCT06140953 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-11

No results posted yet for this study

Summary

Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD

Conditions

  • Metabolic Associated Fatty Liver Disease

Interventions

DRUG

Trimetazidine

trimetazidine at dose 20 mg three times daily to be taken by intervention group

DRUG

Conventional therapy

conventional therapy

DRUG

Placebo

placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only

Sponsors & Collaborators

  • October 6 University

    lead OTHER

Principal Investigators

  • Hoda m rabea, Assistant Professor · Beni-suaf university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-10
Primary Completion
2024-06-01
Completion
2024-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140953 on ClinicalTrials.gov